Beck, Marcus; Böhmer, Dirk; Aebersold, Daniel; Albrecht, Clemens; Flentje, Michael; Ganswindt, Ute; Höcht, Stefan; Hölscher, Tobias; Müller, Arndt-Christian; Niehoff, Peter; Pinkawa, Michael; Sedlmayer, Felix; Zips, Daniel; Zschaeck, Sebastian; Budach, Volker; Wiegel, Thomas; Ghadjar, Pirus (2020). Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer. Strahlentherapie und Onkologie, 196(2), pp. 109-116. Springer 10.1007/s00066-019-01553-3
|
Text
Beck2019_Article_RoleOfCombinedRadiationAndAndr.pdf - Published Version Available under License Publisher holds Copyright. Download (296kB) | Preview |
OBJECTIVE
This article aims to provide an overview of the role of combined radiation and androgen deprivation (ADT) therapy in patients with intermediate-risk prostate cancer.
MATERIALS AND METHODS
The current German, European, and NCCN (National Comprehensive Cancer Network) guidelines as well as relevant literature in the PubMed database which provide information on sub-classification within the intermediate-risk group and the use of ADT in terms of oncological outcome were reviewed.
RESULTS
Different recommendations for risk-group assessment of patients with localized prostate cancer are available. Subdivision of intermediate risk into a favorable and an unfavorable group seems to be justified to allow for a more individualized therapy in a quite heterogenous group of patients. So far, multiple randomized trials have shown a benefit when radiation therapy (RT) is combined with ADT. The use of dose-escalated RT without ADT also appears to be an adequate therapy associated with a very low rate of cancer-specific deaths. Therefore, taking into account the increased rate of toxicity associated with ADT, dose-escalated RT alone might be justified, especially in favorable intermediate-risk patients.
CONCLUSION
Dose-escalated RT alone appears to be an appropriate treatment in favorable intermediate-risk patients. Addition of short course ADT (4-6 months) might improve outcomes in unfavorable intermediate-risk patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology |
UniBE Contributor: |
Aebersold, Daniel Matthias, Ghadjar, Pirus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1439-099X |
Publisher: |
Springer |
Language: |
English |
Submitter: |
Beatrice Scheidegger |
Date Deposited: |
18 Dec 2019 16:23 |
Last Modified: |
01 Dec 2023 00:25 |
Publisher DOI: |
10.1007/s00066-019-01553-3 |
PubMed ID: |
31784804 |
Uncontrolled Keywords: |
Androgen deprivation therapy Dose-escalation Intermediate risk Prostate cancer Radiation therapy |
BORIS DOI: |
10.7892/boris.136414 |
URI: |
https://boris.unibe.ch/id/eprint/136414 |
Actions (login required)
 |
Edit item |